Literature DB >> 17874451

The prognostic significance of leukemic cells clearance kinetics evaluation during the initial course of induction therapy with HAD (homoharringtonine, cytosine arabinoside, daunorubicin) in patients with de novo acute myeloid leukemia.

Zhijian Xiao1, Hua Xue, Rui Li, Li Zhang, Minghua Yu, Yushu Hao.   

Abstract

The impact of the percentage of residual leukemic cells (RLCs) at the end of first course of induction chemotherapy (T1) or during aplasia (T2) on complete remission (CR) rate, disease-free survival (DFS), and overall survival (OS) were retrospectively analyzed in 72 cases of de novo acute myeloid leukemia (AML) treated with HAD (homoharringtonine, cytosine arabinoside, and daunorubicin) regimen. The patients were separated into two subgroups by a cutoff of 10% bone marrow leukemic cells at T1 or T2 time point. The CR rate, DFS, and OS were significantly different between the two groups. We further confirmed that the percentage of RLCs at T1 or T2 is an independent prognostic factor of AML. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17874451     DOI: 10.1002/ajh.21068

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  5 in total

1.  Novel homobarringtonie-containing therapy for the treatment of patients with primary acute myeloid leukemia that are resistant to conventional therapy.

Authors:  Jingsong He; Li Li; Jingjing Zhu; Weiyan Zheng; Wenjun Wu; Yanlong Zheng; Xiujin Ye
Journal:  Oncol Lett       Date:  2017-09-27       Impact factor: 2.967

2.  Re-induction therapy in adult patients with acute myeloid leukemia with ≤20 % blasts: A retrospective cohort study.

Authors:  Kavya K Kannan; Paz Vellanki; Scott Isom; Bernard Tawfik; Allison Winter; Heidi D Klepin; Leslie R Ellis; Rupali Roy Bhave; Dianna Howard; Megan Manuel; Sarah Dralle; Susan Lyerly; Bayard L Powell; Timothy S Pardee
Journal:  Leuk Res       Date:  2021-10-21       Impact factor: 3.156

3.  Leukemia With TCF3-ZNF384 Rearrangement as a Distinct Subtype of Disease With Distinct Treatments: Perspectives From A Case Report and Literature Review.

Authors:  Na Lin; Xiaojing Yan; Dali Cai; Lei Wang
Journal:  Front Oncol       Date:  2021-07-28       Impact factor: 6.244

4.  Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy.

Authors:  João Tadeu D Souto Filho; Monique M Loureiro; Wolmar Pulcheri; José Carlos Morais; Marcio Nucci; Rodrigo D Portugal
Journal:  Diagn Pathol       Date:  2015-07-25       Impact factor: 2.644

Review 5.  Homoharringtonine and omacetaxine for myeloid hematological malignancies.

Authors:  Shuqing Lü; Jianmin Wang
Journal:  J Hematol Oncol       Date:  2014-01-03       Impact factor: 17.388

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.